Your browser doesn't support javascript.
loading
SMYD5 acts as a potential biomarker for hepatocellular carcinoma.
Chi, Gang; Pei, Jinhong; Li, Xueqing; Li, Xujiong; Pang, Hui; Cui, Jia; Wu, Dongkai; Qu, Gexi; He, Yuan.
Afiliação
  • Chi G; Department of Biochemistry, Changzhi Medical College, Changzhi, Shanxi, 046000, China.
  • Pei J; Department of Biochemistry, Changzhi Medical College, Changzhi, Shanxi, 046000, China.
  • Li X; Department of Biochemistry, Changzhi Medical College, Changzhi, Shanxi, 046000, China.
  • Li X; Department of Physiology, Changzhi Medical College, Changzhi, Shanxi, 046000, China.
  • Pang H; Department of Immunology, Changzhi Medical College, Changzhi, Shanxi, 046000, China.
  • Cui J; Department of Microbiology, Changzhi Medical College, Changzhi, Shanxi, 046000, China.
  • Wu D; Changzhi Medical College, Changzhi, Shanxi, 046000, China.
  • Qu G; Changzhi Medical College, Changzhi, Shanxi, 046000, China.
  • He Y; Department of General Surgery, Heping Hospital, Changzhi Medical College, Changzhi, Shanxi, 046000, China. Electronic address: heyuan820827@163.com.
Exp Cell Res ; 414(2): 113076, 2022 05 15.
Article em En | MEDLINE | ID: mdl-35218722
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Exp Cell Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Exp Cell Res Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China